Review of the prescription of antipsychotics in children
Review of the prescription of antipsychotics in children. In France, as in the rest of the world, prescribing of antipsychotic drugs increases in children and adolescentsIndeed, antipsychotics are frequently prescribed in children and adolescents for both psychotic and non-psychotic disorders, with 36 to 93%o fprescriptionsbeingoff-label in this population. In addition, a high number of adverse events have been reported in the literature under antipsychotic treatment. The consequences of these adverse events are still poorly documented. In France, a 12-months national prospective study (ETAPE) observed a high incidence rate, severity and persistence of adverse events during first-time antipsychotic treatment in pediatric patients. Therefore, a careful and continuous clinical and biological monitoring all over the treatment period is required to adapt treatment decisions based on benefice-risk-analysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:70 |
|---|---|
| Enthalten in: |
La Revue du praticien - 70(2020), 5 vom: 25. Mai, Seite 502-506 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
État des lieux de la prescription des antipsychotiques chez l’enfant |
|---|
| Beteiligte Personen: |
Menard, Marie-Line [VerfasserIn] |
|---|
| Themen: |
Antipsychotic Agents |
|---|
| Anmerkungen: |
Date Completed 19.10.2020 Date Revised 19.10.2020 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM316281743 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316281743 | ||
| 003 | DE-627 | ||
| 005 | 20231225160739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316281743 | ||
| 035 | |a (NLM)33058634 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Menard, Marie-Line |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Review of the prescription of antipsychotics in children |
| 246 | 3 | 3 | |a État des lieux de la prescription des antipsychotiques chez l’enfant |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2020 | ||
| 500 | |a Date Revised 19.10.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Review of the prescription of antipsychotics in children. In France, as in the rest of the world, prescribing of antipsychotic drugs increases in children and adolescentsIndeed, antipsychotics are frequently prescribed in children and adolescents for both psychotic and non-psychotic disorders, with 36 to 93%o fprescriptionsbeingoff-label in this population. In addition, a high number of adverse events have been reported in the literature under antipsychotic treatment. The consequences of these adverse events are still poorly documented. In France, a 12-months national prospective study (ETAPE) observed a high incidence rate, severity and persistence of adverse events during first-time antipsychotic treatment in pediatric patients. Therefore, a careful and continuous clinical and biological monitoring all over the treatment period is required to adapt treatment decisions based on benefice-risk-analysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Child | |
| 650 | 4 | |a Neuroleptics | |
| 650 | 4 | |a Side effects | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 700 | 1 | |a Fernandez, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Thümmler, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Askenazy, Florence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue du praticien |d 1951 |g 70(2020), 5 vom: 25. Mai, Seite 502-506 |w (DE-627)NLM000023248 |x 2101-017X |7 nnns |
| 773 | 1 | 8 | |g volume:70 |g year:2020 |g number:5 |g day:25 |g month:05 |g pages:502-506 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 70 |j 2020 |e 5 |b 25 |c 05 |h 502-506 | ||